EX-10.6 5 a11-28276_4ex10d6.htm EX-10.6 CO-EXCLUSIVE SUBLICENSE AGREEMENTCo-Exclusive Sublicense Agreement • May 5th, 2020 • Delaware
THIS CO-EXCLUSIVE SUBLICENSE AGREEMENT (“Agreement”) effective as of the date of last signature below (the “Effective Date”) is by and between XENOMICS, Inc., a Florida corporation having its principal office at 420 Lexington Avenue Suite 1701 New York, NY 10170 USA, United States of America (“XENOMICS”) and ASURAGEN, Inc., a Delaware corporation having its principal office at 2150 Woodward, Suite 100, Austin, TX 78744 (“ASURAGEN”).
AMENDMENT TO CO-EXCLUSIVE SUBLICENSE AGREEMENTCo-Exclusive Sublicense Agreement • February 15th, 2012 • TrovaGene Inc. • Biological products, (no disgnostic substances)
This Amendment (“Amendment”), is made June 1, 2010 (the “Effective Date”) between Asuragen, Inc. (“ASURAGEN”), a Delaware corporation having its principal offices at 2150 Woodward, Suite 100, Austin, Texas 78744, and Trovagene, Inc. (“TROVAGENE”), a Delaware corporation having its principal place of business at 11055 Flintkote Ave., San Diego, CA 92121, which collectively may be referred to herein as the “Parties” and individually as a “Party”.
AMENDMENT TO CO-EXCLUSIVE SUBLICENSE AGREEMENTCo-Exclusive Sublicense Agreement • February 15th, 2012 • TrovaGene Inc. • Biological products, (no disgnostic substances)
This Amendment (“Amendment”), is made September 1, 2010 (the “Effective Date”) between Ipsogen SAS, a French corporation having its principal office at Luminy Biotech Enterprises Case 923, 163 Avenue de Luminy 13288 Marseille cedex 9 France (IPSOGEN”), and Trovagene, Inc. (“TROVAGENE”), a Delaware corporation having its principal place of business at 11055 Flintkote Ave., San Diego, CA 92121, which collectively may be referred to herein as the “Parties” and individually as a “Party”.
